Search
Maralixibat
go.drugbank.com/drugs/DB16226ApprovedInvestigational[A239249] No clinical trials have been performed to assess the efficacy of these treatments for cholestatic pruritus and treatments were given based on a prescriber's clinical experience. … Maralixibat (also known as SHP625, LUM001, and lopixibat) is an ileal bile acid transporter inhibitor, like [odevixibat].
Depemokimab
go.drugbank.com/drugs/DB18846ApprovedInvestigational[A275338] Approved by the FDA on December 16, 2025, depemokimab is indicated as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in adult and paediatric patients … Depemokimab is a humanized Immunoglobulin G1 (IgG1) monoclonal antibody and a long-acting drug.
Telisotuzumab vedotin
go.drugbank.com/drugs/DB15104ApprovedInvestigationalTelisotuzumab vedotin is an antibody-drug conjugate comprising [telisotuzumab], a c-Met-directed humanized IgG1κ monoclonal antibody, conjugated to monomethyl auristatin E (MMAE), a small molecule microtubule-disrupting … agent, via a protease-cleavable valine-citrulline linker.
Hexylcaine
go.drugbank.com/drugs/DB00473ApprovedWithdrawnHexylcaine hydrochloride is also known as cyclaine and osmocaine. It is a short acting local anesthetic that acts through inhibition of sodium channels. … Patients experience an overdose may present with headache, tinnitus, numbness and tingling around the mouth and tongue, convulsions, inability to breathe, and decreased heart function.
Lixisenatide
go.drugbank.com/drugs/DB09265ApprovedInvestigationalIt is sold by Sanofi-Aventis under the brand name Adlyxin in the US[L763] and Lyxumia in the EU.[L764] Adlyxin recieved FDA approval July 28, 2016.[L763] … Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM).
Mixtures: SOLİQUA SOLOSTAR 100 U/ML + 33 MCG/ML SC ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 5 KALEM, SOLİQUA SOLOSTAR 100 U/ML + 50 MCG/ML SC ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 5 KALEMChlorquinaldol
go.drugbank.com/drugs/DB13306Approved[F4549] It was marketed in the 1950s as an iodine-free alternative which was also unrelated to sulfa drugs or hormones. … Chlorquinaldol is currently approved by the European Medicines Agency as a combination tablet with promestriene for the treatment of bacterial vaginosis.[F4552]
Fluoroestradiol F-18
go.drugbank.com/drugs/DB15690ApprovedInvestigationalFluoroestradiol F-18 is an imaging agent used with positron emission tomography (PET) to detect estrogen receptor-positive breast cancer lesions.
Cinchocaine
go.drugbank.com/drugs/DB00527ApprovedVet approvedA local anesthetic of the amide type now generally used for surface anesthesia. … It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006)
Categories: Agents for Treatment of Hemorrhoids and Anal Fissures for Topical UseVilanterol
go.drugbank.com/drugs/DB09082ApprovedInvestigational[A7737] This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration). … [A259961] Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds
Sipuleucel-T
go.drugbank.com/drugs/DB06688ApprovedInvestigationalThe treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014. … Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers.